ATAI Life Sciences N.V. Aktie News

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its Phase 2a study of its novel intranasal 5-MeO-MDT drug candidate BPL-003 in treatment-resistant depression. Initial results from the first part of the study unveiled in March showed that a single dose of BPL-003 was safe and well-tolerated and had a “rapid and durable” a...

NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech's Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Re...

In a bullish endorsement for Arecor Therapeutics PLC (AIM:AREC), Panmure Gordon has issued a 'buy' recommendation, underpinning a significant upside potential with a target price of 539p — over four times the current share price of 132p. Known for its innovative diabetes treatments, Arecor is expected to pick up royalties from AT220 product, its new insulin formulation, that could generate a su...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytech's Phase 1 study of its novel, novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, BPL-003, have been published in The Journal of Psychopharmacology. The study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of BPL-003 in combination with psycholo...

NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech's novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychop...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression.   CEO and co-founder Florian Brand joined Proactive to discuss the company's recent milestones including encouraging clinical trial results, what to expect from its ongoing research programs and upcoming cata...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its operations into 2026 as it continues to advance psychedelic-based therapies targeting several mental health conditions. Recent clinical highlights included positive results from Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of 5-MeO-DMT,...

NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.